Evidence map›Paper›PMID 35612315›Full record

ArticleMicrobiology spectrum2022

Development and Implementation of Dried Blood Spot-Based COVID-19 Serological Assays for Epidemiologic Studies.

Marcus P Wong, Michelle A Meas, Cameron Adams, Samantha Hernandez, Valerie Green, Magelda Montoya, Brett M Hirsch, Mary Horton, Hong L Quach, Diana L Quach and 15 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Marcus P WongDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.ORCID 0000-0001-6554-2976
Michelle A MeasDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Cameron AdamsDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Samantha HernandezDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Valerie GreenCreative Testing Solutions, Tempe, Arizona, USA.
Magelda MontoyaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Brett M HirschOrtho Clinical Diagnostics, Rochester, New York, USA.
Mary HortonDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Hong L QuachDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Diana L QuachDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Xiaorong ShaoDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Indro FedrigoDivision of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Alexandria ZermenoDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Julia HuffakerDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Raymond MontesDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Alicia MaddenDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Sherri CyrusCreative Testing Solutions, Tempe, Arizona, USA.
David McDowellCreative Testing Solutions, Tempe, Arizona, USA.
Phillip WilliamsonCreative Testing Solutions, Tempe, Arizona, USA.
Paul ContestableOrtho Clinical Diagnostics, Rochester, New York, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.
Josefina ColomaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Michael P Busch *Vitalant Research Institute, San Francisco, California, USA.
Lisa F Barcellos *Division of Epidemiology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.
Eva Harris *Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeleygrid.47840.3f, Berkeley, California, USA.ORCID 0000-0002-7238-4037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serological surveillance studies of infectious diseases provide population-level estimates of infection and antibody prevalence, generating crucial insight into population-level immunity, risk factors leading to infection, and effectiveness of public health measures. These studies traditionally rely on detection of pathogen-specific antibodies in samples derived from venipuncture, an expensive and logistically challenging aspect of serological surveillance. During the COVID-19 pandemic, guidelines implemented to prevent the spread of SARS-CoV-2 infection made collection of venous blood logistically difficult at a time when SARS-CoV-2 serosurveillance was urgently needed. Dried blood spots (DBS) have generated interest as an alternative to venous blood for SARS-CoV-2 serological applications due to their stability, low cost, and ease of collection; DBS samples can be self-generated via fingerprick by community members and mailed at ambient temperatures. Here, we detail the development of four DBS-based SARS-CoV-2 serological methods and demonstrate their implementation in a large serological survey of community members from 12 cities in the East Bay region of the San Francisco metropolitan area using at-home DBS collection. We find that DBS perform similarly to plasma/serum in enzyme-linked immunosorbent assays and commercial SARS-CoV-2 serological assays. In addition, we show that DBS samples can reliably detect antibody responses months postinfection and track antibody kinetics after vaccination. Implementation of DBS enabled collection of valuable serological data from our study population to investigate changes in seroprevalence over an 8-month period. Our work makes a strong argument for the implementation of DBS in serological studies, not just for SARS-CoV-2, but any situation where phlebotomy is inaccessible.

Indexed as

COVID-19Antibodies, ViralEpidemiologic StudiesHumansPandemicsSARS-CoV-2Seroepidemiologic StudiesAntibodies, ViralantibodiesCOVID-19dried blood spotSARS-CoV-2serologyseroprevalence

Identifiers

PMID35612315
PMCPMC9241704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.